DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 200 filers reported holding DENALI THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 9.23 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $36,515 | -95.2% | 1,313 | -94.7% | 0.00% | -100.0% |
| Q3 2022 | $767,000 | +33.6% | 25,000 | +94.2% | 0.00% | 0.0% |
| Q4 2021 | $574,000 | +78.8% | 12,874 | +102.3% | 0.00% | +100.0% |
| Q3 2021 | $321,000 | -96.0% | 6,364 | -93.8% | 0.00% | -97.4% |
| Q2 2021 | $7,996,000 | +105.6% | 101,934 | +49.7% | 0.04% | +100.0% |
| Q1 2021 | $3,889,000 | -7.3% | 68,102 | +36.0% | 0.02% | -17.4% |
| Q4 2020 | $4,194,000 | +83.0% | 50,074 | -21.7% | 0.02% | +35.3% |
| Q3 2020 | $2,292,000 | +141.3% | 63,960 | +17.9% | 0.02% | +54.5% |
| Q1 2020 | $950,000 | -62.0% | 54,266 | -54.9% | 0.01% | -31.2% |
| Q2 2019 | $2,500,000 | – | 120,402 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
| Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
| Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
| Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
| A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
| MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
| Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
| Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
| GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
| IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |